Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 279,300 shares, a growth of 466.5% from the March 15th total of 49,300 shares. Currently, 37.3% of the company’s shares are short sold. Based on an average daily trading volume, of 2,720,000 shares, the days-to-cover ratio is presently 0.1 days.

Windtree Therapeutics Price Performance

WINT opened at $1.18 on Wednesday. Windtree Therapeutics has a 12 month low of $1.10 and a 12 month high of $737.44. The business has a 50-day moving average of $2.89 and a two-hundred day moving average of $18.27. The stock has a market capitalization of $883,820.00, a price-to-earnings ratio of -0.07 and a beta of 0.91.

Institutional Investors Weigh In On Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new position in Windtree Therapeutics, Inc. (NASDAQ:WINT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics at the end of the most recent quarter. 29.33% of the stock is owned by institutional investors and hedge funds.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.